Recent Company News

• 08:06 AM ET Jun 24, 2025
  

  Radiopharm Theranostics and Cyclotek sign clinical supply agreement for ¹⁶¹Tb-KLK3-mAb phase I clinical trial in Australia ($4.39, 0.00)

• 06:31 PM ET Jun 10, 2025
  

  Radiopharm Theranostics granted Fast Track Designation by US FDA for RAD101 in imaging of brain metastasis ($4.97, 0.00)

• 06:33 PM ET Jun 03, 2025
  

  Radiopharm Theranostics doses first patient in its Phase 1 HEAT clinical trial of RAD202 ($4.90, 0.00)

• 07:18 PM ET Jun 01, 2025
  

  Radiopharm Theranostics reports positive preclinical Lu177-B7H3-mAb data ($4.65, 0.00)

• 06:28 PM ET May 18, 2025
  

  Radiopharm Theranostics, ITM sign supply agreement for n.c.a. Lutetium-177 ($4.15, 0.00)

• 07:07 AM ET May 12, 2025
  

  Radiopharm Theranostics initiated buy at ThinkEquity ($4.18, 0.00)

• 06:51 PM ET May 11, 2025
  

  DSMC approves Radiopharm Theranostics to proceed to the next dose in 177Lu-RAD204 Phase 1 clinical trial ($4.18, 0.00)

• 12:06 PM ET May 01, 2025
  

  Radiopharm Theranostics initiated buy at Maxim Group (pre-open) ($4.09, +0.18)

• 08:20 PM ET Apr 28, 2025
  

  Radiopharm Theranostics reports Q3 net cash from / (used in) operating activities (A$7.4M) - Appendix 4C ($3.99, 0.00)

• 07:36 PM ET Apr 27, 2025
  

  Radiopharm Theranostics doses first patient with 18F-RAD101 in phase 2b imaging study of brain metastasis ($4.07, 0.00)